Straits Times Index
3,307.90 -6.15 (-0.19%) S&P 500
5,311.55 -9.86 (-0.19%) Dow
39,749.29 -123.70 (-0.31%) Nasdaq
16,801.29 -31.34 (-0.19%) Bitcoin USD
69,840.05 +186.70 (+0.27%) CMC Crypto 200
1,524.66 -1.76 (-0.12%)
AbbVie Inc. (ABBV)
| Previous close | 162.93 |
| Open | 165.37 |
| Bid | 160.73 x 800 |
| Ask | 160.78 x 1200 |
| Day's range | 159.18 - 161.94 |
| 52-week range | 130.96 - 182.89 |
| Volume | |
| Avg. volume | 5,586,153 |
| Market cap | 283.872B |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | 47.84 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 6.20 (3.81%) |
| Ex-dividend date | 12 Apr 2024 |
| 1y target est | N/A |
- PR Newswire
AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®
AbbVie (NYSE: ABBV) announced it is presenting 15 abstracts at the 2024 Digestive Disease Week (DDW) Annual Meeting, being held May 18-21 in Washington, D.C., and virtually.
- PR Newswire
AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals today announced a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders. This collaboration will leverage AbbVie's expertise in psychiatry and Gilgamesh's innovative research platform to discover novel neuroplastogens.
- CNW Group
QULIPTA™ (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in Adults
AbbVie (NYSE: ABBV) announced today that Health Canada has approved QULIPTA (atogepant) for the prevention of migraine in adults who have at least four migraine days per month.1 QULIPTA is the first and only oral, small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) approved to prevent both episodic and chronic migraine.
